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recOBJECTIVES This study sought to compare, in high-risk patients with 3þ to 4þmitral regurgitation (MR) dichotomized
by baseline echocardiographic features, acute, 30-day, and 12-month outcomes following percutaneous mitral valve
repair using the MitraClip.
BACKGROUND The feasibility and mid-term outcomes after MitraClip implantation in patients with echocardiographic
features different from the EVEREST (Endovascular Valve Edge-to-Edge Repair) I and II trials have been scarcely studied.
METHODS Clinical and echocardiographic outcomes through 12-month follow-up of consecutive patients who
underwent MitraClip implantation were obtained from an ongoing prospective registry. Two different groups, divided
according to baseline echocardiographic criteria (investigational group [EVERESTOFF] and control group [EVERESTON]),
were compared.
RESULTS Seventy-eight patients were included in EVERESTOFF and 93 patients in EVERESTON groups. Important and
comparable acute reductions in MR and no clip-related complications were revealed. The primary safety endpoint at
30 days was comparable between groups (2.6% vs. 6.5%, respectively, p ¼ 0.204); in addition, MR reduction was
mostly sustained, whereas equivalent improvement in New York Heart Association functional class were demonstrated.
Kaplan-Meier freedom from death, surgery for mitral valve dysfunction, or grade $3þ MR at 12 months was demon-
strated in 71.4% and 76.2%, respectively, in the EVERESTOFF and EVERESTON groups (log rank p ¼ 0.378). Signiﬁcant
improvements in ejection fraction and reduction in left ventricle volumes were demonstrated in both groups over time,
but the baseline between-group differences were sustained.
CONCLUSIONS MitraClip implantation in patients with expanded baseline echocardiographic features, compared
with the control group, was associated with similar rates of safety and efﬁcacy through 12-month follow-up. Further
validation of our ﬁndings is warranted. (J Am Coll Cardiol Intv 2015;8:74–82) © 2015 by the American College of
Cardiology Foundation.m the *Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy; yHarrington Heart and Vascular
titute, University Hospitals, Case Medical Center, Cleveland, Ohio; zInterventional Cardiology Department, Pitangueiras
spital, Jundiai, São Paulo, Brazil; xDepartment of Cardiology, Tokai University School of Medicine, Isehara, Japan; and the
xcellence Through Newest Advances (ETNA) Foundation, Catania, Italy. Dr. Attizzani is a consultant with Medtronic; and has
eived consulting fees from St. Jude Medical. Dr. Ohno is supported by a grant from the Japan Heart Foundation and Bayer
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 , 2 0 1 5 Attizzani et al.
J A N U A R Y 2 0 1 5 : 7 4 – 8 2 MitraClip Implantation Beyond EVEREST Criteria
75AB BR E V I A T I O N S
AND ACRONYM S
EF = ejection fraction
LV = left ventricle
MR = mitral regurgitation
NYHA = New York Heart
AssociationS evere mitral regurgitation (MR) leads to incre-mental left ventricle (LV) dysfunction andincreasing rates of hospitalization for heart
failure (1). Although mitral valve surgery is the gold
standard therapy in patients with moderate-to-
severe (3þ) or severe (4þ) MR associated with symp-
toms or evidence of LV dysfunction (2), its beneﬁts
are controversial in functional MR, where lack of sur-
vival beneﬁt and high rates of recurrence have been
demonstrated (3). In addition, morbidity and mortal-
ity among high-risk patients that undergo mitral
valve surgery are relevant in this setting (4,5), which
explains why a substantial proportion of patients is
referred to isolated medical management rather
than surgery in daily clinical practice. Notably,
although medical therapy mitigates symptoms, it
does not modify the progression of the disease (6).
Percutaneous edge-to-edge mitral valve repair with
the MitraClip system (Abbott Vascular, Abbott Park,
Illinois) recently emerged as a viable, less invasive,
therapeutic option in patients with 3þ or 4þ MR
associated with high surgical risk (7). Patients from
the initial experience, as well as the ones included in
the only randomized controlled trial conducted so
far, however, had to fulﬁll strict echocardiographic
criteria to be considered suitable for MitraClip
therapy, which largely limited its indications (7,8).
Conversely, real-world registries broadened the in-
dications for MitraClip implantation and a signiﬁcant
amount of included patients did not meet the previ-
ously established echocardiographic criteria (9,10),
but data regarding early and mid-term outcomes in
this subset are lacking. On this background, we aimed
at assessing the 30-day and 12-month clinical and
echocardiographic outcomes after MitraClip implan-
tation in real-world patients who did not meet the key
echocardiographic eligibility criteria determined by
the EVEREST (Endovascular Valve Edge-to-Edge
Repair) I and II studies (7,8).
METHODS
PATIENTS AND PROCEDURES. Patients with symp-
toms or signs of LV deterioration and 3þ or 4þ MR
determined by combined transthoracic and trans-
esophageal echocardiogram (11) considered to be at
high surgical risk by an interdisciplinary team of
cardiologists, interventional cardiologists, cardiacYakuhin Research Grant Abroad. Dr. Grasso is a proctor for MitraClip for Ab
they have no relationships relevant to the contents of this paper to disclose.
authors for this manuscript. Drs. Capranzano and Grasso contributed equal
Manuscript received April 17, 2014; revised manuscript received June 15, 20surgeons, and anesthesiologists underwent
percutaneous edge-to-edge mitral valve
repair with MitraClip at Ferrarotto Hospital,
University of Catania, Catania, Italy, from
August 1, 2008 to December 31, 2013 as part of
the ongoing GRASP (Getting Reduction of
Mitral Insufﬁciency by Percutaneous Clip
Implantation) registry; the results of which
have been partly published elsewhere (9). After
receiving a complete oral and written explanation of
the issues surrounding the procedure, all patients
included in the study provided written consent. The
study was approved by the local ethics committee.
Qualifying inclusion and exclusion criteria for Mitra-
Clip therapy (clinical and echocardiographic), as well
as details of the procedure have been previously re-
ported (12). Data were obtained from the MitraClip
electronic database of Ferrarotto Hospital. Echocar-
diographic data were separately analyzed by a team
of 2 expert echocardiographists and reviewed by a
third reader for consensus when there was disagree-
ment. The study groups were deﬁned based on pre-
viously published echocardiographic criteria from the
EVEREST I and II trials (7,8) as follows: 1) valve ge-
ometry features: coaptation length $2 mm, coapta-
tion depth <11 mm, ﬂail gap <10 mm, ﬂail width <15
mm; and 2) ventricle function/geometry: ejection
fraction [EF] >25%, and LV end-systolic diameter #55
mm. Patients that did not fulﬁll these criteria repre-
sented the investigational group (i.e., EVERESTOFF
group), whereas patients that fulﬁlled these criteria
represented the control group (i.e., EVERESTON
group). Clinical and echocardiographic outcomes,
which were prospectively collected at 30-day and 12-
month follow-ups, were then compared between the
2 groups.
ENDPOINTS. Acute device success was deﬁned as
residual MR #2þ after clip implantation. The primary
safety endpoint was the incidence of major adverse
events at 30 days, deﬁned as the composite of death,
myocardial infarction, reoperation for failed Mitra-
Clip implantation, nonelective cardiovascular surgery
for adverse events, stroke, renal failure, deep wound
infection, mechanical ventilation for >48 h, gastro-
intestinal complication requiring surgery, new-onset
of permanent atrial ﬁbrillation, septicemia, and
transfusion of 2 U of blood. The primary efﬁcacybott Vascular. All other authors have reported that
Drs. Attizzani and Ohno contributed equally as ﬁrst
ly as senior authors for this manuscript.
14, accepted July 16, 2014.
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76endpoint was freedom from death, surgery for mitral
valve dysfunction, or grade $3þ MR at 12-month
follow-up after clip implantation, whereas the same
parameters were evaluated as a secondary efﬁcacy
endpoint at 30 day.
STATISTICAL ANALYSIS. Continuous variables
following a normal distribution are presented as
mean  SD and were compared using the Student
unpaired t test for comparisons between groups and
paired t test for within-group comparisons. Variables
that did not follow a normal distribution were
compared with a Mann-Whitney U test for compari-
sons between groups and a Wilcoxon signed rank testBaseline Characteristics
EVERESTOFF
(n ¼ 78)
EVERESTON
(n ¼ 93) p Value
71.65  9.13 71.86  10.40 0.887
52 (66.7) 54 (58.1) 0.248
ion 59 (75.6) 68 (73.1) 0.707
28 (35.9) 32 (34.4) 0.839
llation 35 (44.9) 32 (34.4) 0.163
19 (24.4) 18 (19.4) 0.429
CI 26 (33.3) 28 (30.1) 0.651
ardiac surgery 16 (20.5) 29 (31.2) 0.115
re 41 (52.6) 41 (44.1) 0.269
yocardial infarction 29 (37.2) 29 (31.2) 0.409
troke 8 (10.3) 6 (6.5) 0.366
uroSCORE II 7.45  6.35 8.10  7.12 0.541
mortality 6.06  6.76 6.92  7.17 0.425
l MR 68 (87.2) 78 (83.9) 0.542
32.18  12.83 40.17  11.99 <0.001
l 205.79  80.62 132.33  38.56 <0.001
l 148.25  74.23 78.23  33.54 <0.001
m 52.57  13.05 37.80  8.96 <0.001
m 66.43  10.67 54.92  7.44 <0.001
volume, ml 106.92  54.20 89.29  36.64 0.026
e area, cm2 4.11  0.91 4.06  0.77 0.718
e gradient, mm Hg 1.82  1.00 1.91  0.97 0.586
0.062
0 (0) 0 (0)
1 (1.3) 4 (4.3)
31 (39.7) 50 (53.8)
46 (59) 39 (41.9)
ctional class 0.632
0 (0) 1 (1.1)
13 (16.7) 18 (19.4)
54 (69.2) 65 (69.9)
11 (14.1) 9 (9.7)
ean  SD or n (%).
chronic obstructive pulmonary disease; EuroSCORE ¼ European System for Cardiac
isk Evaluation; EVERESTOFF ¼ investigational group of Endovascular Valve Edge-to-
trial; EVERESTON ¼ control group of Endovascular Valve Edge-to-Edge Repair trial;
l regurgitation; LVEDD ¼ left ventricle end-diastolic diameter; LVEDV ¼ left ventricle
ic volume; LVEF ¼ left ventricle ejection fraction; LVESD ¼ left ventricle end-systolic
VESV ¼ left ventricle end-systolic volume; NYHA ¼ New York Heart Association;
taneous coronary intervention; STS ¼ Society of Thoracic Surgeons.for within-group comparisons. Categorical variables
are presented as counts and percentages and were
compared by the chi-square or the Fisher exact
test. Survival curves were generated using the
Kaplan-Meier method, and log-rank tests were used
to evaluate differences between groups. A 2-way
repeated-measures analysis of variance was used to
evaluate the effects of time (baseline vs. 30-day
follow-up vs. 12-month follow-up) and group
(EVERESTOFF vs. EVERESTON) on echocardiographic
and clinical variables, and post-hoc analysis was
performed with Bonferroni correction. All p values
reported are 2-sided, and p values <0.05 were
considered signiﬁcant. All data were processed using
the Statistical Package for the Social Sciences (version
21 (SPSS Inc., Chicago, Illinois).
RESULTS
BASELINE CHARACTERISTICS. A total of 171
consecutive patients were included. Among the
78 patients included in the EVERESTOFF group,
35 patients had EF #25%, 28 patients had LV end-
systolic diameter >55 mm, 34 patients had coapta-
tion depth $11 mm, and 10 patients had the ﬂail
width $15 mm. Baseline clinical characteristics were
well balanced between the groups, whereas marked
differences were demonstrated in echocardiographic
parameters, as follows: signiﬁcantly larger dimen-
sions of LV and left atrium, as well as lower EF and a
nonsigniﬁcant trend toward more MR grade 4þ were
identiﬁed in the EVERESTOFF (n ¼ 78) than in the
EVERESTON (n ¼ 93) group. No differences were
noted, however, in the baseline distribution of New
York Heart Association (NYHA) functional classes
between the groups (Table 1).
ACUTE AND 30-DAY OUTCOMES. Remarkable and
comparable reductions in MR were observed in the
vast majority of patients in both groups immediately
after the procedure (MR grade # 1þ: 78.4% and 75.5%;
MR grade 2þ: 19.4% and 24.5%; MR grade 3þ: 2.2%
and 0%; and MR grade 4D: 0% and 0%, respectively,
for the EVERESTOFF and EVERESTON groups, p for all
comparisons ¼ 0.523). Accordingly, the rates of acute
device success were high and equivalent between the
2 groups (97.8% vs. 100.0%, respectively, p ¼ 0.294).
Post-procedure mitral valve areas (2.57  0.7 2 cm2 vs.
2.71  0.65 cm2, respectively, for EVERESTOFF and
EVERESTON groups, p ¼ 0.265) and gradients (3.28 
1.63 mm Hg vs. 3.42  1.78 mm Hg, respectively,
p ¼ 0.633) were also comparable. All the clips were
deployed without complications, including clip
embolization, cardiac tamponade or periprocedural
TABLE 2 30-Day Outcomes
EVERESTOFF
(n ¼ 78)
EVERESTON
(n ¼ 93) p Value
Death 1 (1.3) 2 (2.2) 0.566
Myocardial infarction 0 (0) 0 (0) —
Surgery for failed MitraClip 0 (0) 0 (0) —
Emergent cardiovascular surgery 0 (0) 0 (0) —
Deep wound infection 0 (0) 0 (0) —
Mechanical ventilation for >48 h 0 (0) 0 (0) —
Gastrointestinal complication requiring surgery 0 (0) 0 (0) —
Stroke 1 (1.3) 0 (0) 0.447
Renal failure after MitraClip 0 (0) 0 (0) —
New onset of atrial ﬁbrillation 0 (0) 2 (2.2) 0.305
Septicemia 0 (0) 1 (1.1) 0.556
Blood transfusion 1 (1.3) 1 (1.1) 0.695
Rehospitalization for heart failure 2 (2.6) 1 (1.1) 0.437
MR grade (n ¼ 168)* 0.318
1þ 41 (53.2) 38 (41.8)
2þ 32 (41.6) 46 (50.5)
3þ 4 (5.2) 7 (7.7)
4þ 0 (0) 0 (0)
NYHA functional class (n ¼ 168)* 0.048
I 31 (40.3) 27 (29.7)
II 25 (32.5) 45 (49.5)
III 18 (23.4) 19 (20.9)
IV 3 (3.9) 0 (0)
Values are n (%). Dashes indicate that p values are not applicable. *Results expressed based on 168 patients (i.e.,
dead patients were not included).
Abbreviations as in Table 1.
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77stroke. In the EVERESTOFF group, the implantation of
only 1 clip was sufﬁcient to achieve procedural
success in 38 patients (48.7%), whereas in the
EVERESTON group, this number was increased to 58
(62.4%), leading to a trend toward a higher number of
clips per patient in the former EVERESTOFF group
(p ¼ 0.073). Four patients received more than 2 clips
(3 patients in the EVERESTOFF group [2 patients
received 3 clips and 1 patient received 4 clips] and
1 patient in the EVERESTON group [i.e., patient
received 3 clips]). The maximum mitral valve
gradient observed among them was 4.5 mm Hg.
Thirty-day follow-up data were available in 100%
of the patients (Table 2). The primary safety endpoint
(30-day major adverse events) was identiﬁed in
2 patients (2.6%) and 6 (6.5%) in the EVERESTOFF
and EVERESTON groups, respectively (p ¼ 0.204).
Freedom from death, surgery for mitral valve
dysfunction, or grade $3þ MR (secondary efﬁcacy
endpoint) was detected in 72 patients (90.1%) and 82
(93.5%), respectively (p ¼ 0.427). Compared with
post-procedure, MR reduction was mostly sustained
and equivalent between groups (Figure 1, Table 2),
whereas marked improvements in NYHA class
compared with baseline were revealed in both groups
(Figure 2, Table 2). Rehospitalizations for heart failure
were rarely observed in both groups through 30 days
(2 patients [2.6%] vs. 1 patient [1.1%], respectively, in
the EVERESTOFF and EVERESTON groups, p ¼ 0.437).
12-MONTH OUTCOMES. Data from 154 patients (90%)
were available (i.e., the remaining 10% of the patients
did not have sufﬁcient time elapsed from the index
procedure) at 12-month follow-up. Kaplan-Meier
freedom from death, surgery for mitral valve
dysfunction, or grade $3þ MR at 12 months (primary
efﬁcacy endpoint) was demonstrated in 71.4%
and 76.2%, respectively, in the EVERESTOFF and
EVERESTON groups (log rank p ¼ 0.378) (Figure 3). The
components of the primary efﬁcacy endpoint were
also similar between the 2 groups (Table 3).
Paired echocardiographic assessment in patients
with echocardiographic data available at 12 months
(n ¼ 134; i.e., 20 patients from the total of 154 who
were eligible for 12-month follow-up died in the time
frame [9 cardiac and 11 noncardiac deaths], hence, did
not have echocardiographic data available) demon-
strated improvement in the EF and reduction in LV
volumes in both groups comparing baseline and
12-month follow-up. Nonetheless, all the observed
between-group baseline differences in echocardio-
graphic parameters were sustained over time. A
numerical, albeit not statistically signiﬁcant, reduc-
tion in left atrial volume was revealed in both groups(Figure 4). Signiﬁcant reduction in mitral valve area
at 12-month follow-up compared with baseline
(p < 0.001 for both) led to statistically signiﬁcant,
although not clinically concerning increase in mean
mitral valve gradient in both groups (Table 3).
Importantly, w90% of the living patients in both
groups exhibited MR #2þ through 12-month follow-
up (Figure 1, Table 3), whereas w78% were in NYHA
functional class #II in the same time frame (Figure 2,
Table 3).
The rehospitalization rates for heart failure in
the surviving patients were low and comparable
between groups (5 patients [7.1%] vs. 7 patients
[8.3%], respectively, for EVERESTOFF and EVERESTON
groups, p ¼ 0.784). No surgical mitral valve inter-
vention was required during the study period,
whereas an additional clip was implanted in only 2
patients from the EVERESTON group. These reinter-
ventions for additional MitraClip implantation were
not associated with adverse events.
We performed a subanalysis of the investiga-
tional group (i.e., EVERESTOFF) to check whether
different characteristics of inclusion could lead to
different impacts on outcomes through 12-month
follow-up. Three groups were analyzed, as follows:
FIGURE 1 Longitudinal Assessment of MR
Longitudinal assessment of mitral regurgitation (MR) in the investigational (EVERESTOFF)
and control (EVERESTON) groups. EVEREST ¼ Endovascular Valve Edge-to-Edge Repair
trial.
FIGURE 2 Longitu
Longitudinal assessm
EVERESTOFF and EVE
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781) valve geometry; 2) ventricle function/geometry;
and 3) combined group. Although the combined
group revealed numerically lower efﬁcacy (primary
efﬁcacy endpoint 76.2%, 75%, and 62.5%, respec-
tively, p ¼ 0.521), higher rates of MR $3þ (14.5%,
12.5%, and 20.8%, p ¼ 0.710), as well as higher
death rates (9.5%, 12.5%, and 25%, respectively, p ¼
0.312), these differences did not reach statistical
signiﬁcance.
DISCUSSION
The initial clinical experience with the MitraClip
therapy for severe MR demonstrated promising safetydinal Assessment of NYHA Functional Class
ent of New York Heart Association (NYHA) functional class in
RESTON groups. Abbreviations as in Figure 1.and efﬁcacy results, but highly selective echocardio-
graphic criteria substantially limited its indications
(7,8,13). In addition, most of the patients initially
treated with the MitraClip system presented with
preserved EF and degenerative MR, features that do
not completely characterize the broader “real-world”
population that could obtain greater beneﬁt from this
therapy (8). Indeed, observational data from a large
North American institution revealed that 53% of 1,095
patients with severe MR and heart failure were
medically managed; among them, the mean EF was
27  15%, whereas 90% had functional MR, likely due
to controversial results of MV surgery in this setting
(1,3). Recently, European and North American studies
including higher risk patients, mostly with functional
MR, conﬁrmed excellent safety and efﬁcacy proﬁles
of MitraClip implantation in more complex clinical
scenarios, therefore contributing to ﬁll the gap left by
the initial experience (9,10,14,15). Nevertheless, the
early and mid-term clinical and echocardiographic
outcomes of the speciﬁc subgroup of patients that do
not fulﬁll the previously established EVEREST echo-
cardiographic criteria are poorly understood (16),
hence, the rationale for our investigation.
We were able to demonstrate high rates of
successful MitraClip implantation coupled with low
rates of in-hospital adverse events, regardless of
the broadened inclusion echocardiographic criteria,
including larger LV dimensions and poorer LV
function (i.e., EVERESTOFF group features), which
strongly indicates that the favorable safety rates
previously demonstrated for this relatively novel
procedure could be reproduced in more complex
settings (9,14). Goel et al. (1) previously showed high
rates of hospitalization (41%) and mortality (20%),
as well as progressive increase in the use of medica-
tions at 12-month follow-up in nonoperated
patients with severe functional MR and heart
failure. The investigators moreover identiﬁed, using
EVEREST echocardiographic criteria as reference (i.e.,
EVERESTON), a role for MitraClip implantation in 36%
of those patients. Our results are, therefore, insightful
in this context, as they suggest potential room
for expansion of MitraClip therapy indications in
patients that would otherwise be clinically managed,
likely carrying poor long-term prognosis (1). Elderly
patients, in whom surgical treatment of MR is asso-
ciated with elevated perioperative mortality, poor
long-term survival, and uncertain beneﬁt in quality
of life (5), could as well beneﬁt from broader
indications of MitraClip therapy, as advanced age per
se is a frequent cause for surgery denial, whereas if
apparently does not pose a negative impact on the
beneﬁts of MitraClip implantation (17). In fact, the
TABLE 3 12-Month Outcomes
EVERESTOFF
(n ¼ 59)
EVERESTON
(n ¼ 75) p Value
MR $3þ* 11 (15.7) 16 (19.0) 0.588
Death* 11 (15.7) 9 (10.7) 0.358
Surgery for mitral valve dysfunction* 0 (0) 0 (0) —
MR grade 0.681
1þ 29 (49.2) 39 (52.0)
2þ 23 (39.0) 30 (40)
3þ 6 (10.2) 6 (8.0)
4þ 1 (1.7) 0 (0)
Mitral valve area, cm2 2.93  0.81 2.86  0.75 0.679
Mitral valve gradient, mm Hg 3.17  1.16 3.73  1.72 0.087
NYHA functional class 0.388
I 16 (27.1) 29 (38.7)
II 29 (49.2) 29 (38.7)
III 14 (23.7) 16 (21.3)
IV 0 (0) 1 (1.3)
Values are n (%) or mean  SD. Dash indicates that the p value is not applicable. *Results
expressed based on 154 patients used for the calculation of the primary efﬁcacy endpoint (i.e.,
including dead patients through 12-month follow-up).
Abbreviations as in Table 1.
FIGURE 3 Kaplan-Meier Estimates at 12-Month Follow-Up
Kaplan-Meier curves demonstrate (A) freedom from death and (B) freedom from MR $3þ. (C) The combined primary efﬁcacy endpoint is depicted. Abbreviations as in
Figure 1.
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794-year follow-up of the EVEREST II trial suggested a
beneﬁt of MitraClip over surgery in patients $70
years of age (13). Further investigations are required,
however, to evaluate whether MitraClip implantation
leads to better outcomes compared with surgery in
patients with comparable characteristics to our
investigational group (i.e., EVERESTOFF).
Another critical result of the present investigation
was the marked and comparable improvement in MR
obtained after the procedure in both groups
(i.e., w98% of patients with MR #2þ), regardless of
the different baseline echocardiographic features.
This ﬁnding is particularly important because low
grades of MR after MitraClip implantation (i.e., #2þ)
lead to better reverse remodeling (18) and are
inversely correlated with long-term survival after the
intervention (15,19). Furthermore, the signiﬁcant
improvement in MR remained comparable between
EVERESTOFF and EVERESTON groups at 30-day (i.e.,
w95% of living patients with MR #2þ) and 12-month
(i.e.,w90% of living patients with MR #2þ) follow-up
(p ¼ 0.402 for between-group comparison over time).
Recently, Whitlow et al. (14) reported 78% of MR
grade #2þ at 12-month follow-up after MitraClip im-
plantation in a population characterized by high
baseline clinical risk (w60% functional MR); likewise,
Maisano et al. (10) described 78.9% of MR grade #2þ
at 12-month follow-up in a population in whichw77%
of individuals had functional MR. The results
obtained for MR reduction in the EVERESTOFF
group, despite its broader echocardiographic inclu-
sion criteria, are therefore encouraging. Longer
term follow-up is warranted to better characterizethe stability/durability of MR reduction in this
scenario.
Grayburn et al. (18) recently demonstrated, in a
substudy of the EVEREST trials, LV reverse remodel-
ing after reduction of MR to grade 1þ or 2þ secondary
to MitraClip implantation in patients with baseline
functional MR. In line with those data, our control
group (i.e., EVERESTON) exhibited improvement
in EF, as well as signiﬁcant reduction in LV
volumes; importantly, the investigational group (i.e.,
EVERESTOFF) also revealed LV reverse remodeling
FIGURE 4 Baseline and 12-Month Follow-Up Echocardiographic Parameters
The bar graphs demonstrate comparisons between the groups (EVERESTOFF vs. EVERESTON) at baseline and 12-month follow-up (p values for these comparisons are
represented in the light gray square), as well as intragroup comparisons in the 2 different time points (p values are linked to the correspondent graph bars by yellow
lines). LA ¼ left atrium; LVEDV ¼ left ventricle end-diastolic volume; LVESV ¼ left ventricle end-systolic volume; other abbreviations as in Figure 1.
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80through 12-month follow-up (Figure 4) despite its
“more complex” baseline echocardiographic features
(20), but the baseline between-group differences
were sustained over time. Although left atrial
volumes demonstrated similar reduction trends
observed for LV volumes in both groups, the alter-
ations were not statistically signiﬁcant. A type II
statistical error reﬂected by the relatively small
sample size could be a potential explanation for this
ﬁnding. Longer term follow-up and larger sample
sizes are mandatory to completely elucidate the
mechanisms of reverse LV and left atrial remodeling
in this setting.
The clinical signiﬁcance of the reverse LV remod-
eling observed in both groups was reﬂected in
the considerable improvement in NYHA functionalclass, which was observed early after MitraClip im-
plantation (Table 2) and persisted through 12-month
follow-up in both groups (Table 3) (i.e., > 80% of
patients were in NYHA functional class III to IV at
baseline, whereas w78% of patients were in func-
tional class #II at 12-month follow-up; p ¼ 0.573 for
between-group comparisons over time). In addition,
very low rates of death and rehospitalization for heart
failure, coupled with infrequent reinterventions for
additional clip implantation and no need for surgical
mitral valve intervention were revealed. We should
acknowledge, however, that the consistent long-term
clinical (13) and hemodynamic beneﬁts (21) previ-
ously demonstrated after MitraClip implantation in
less complex settings warrant further investigation in
our study population.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 , 2 0 1 5 Attizzani et al.
J A N U A R Y 2 0 1 5 : 7 4 – 8 2 MitraClip Implantation Beyond EVEREST Criteria
81Because the EVEREST I and II echocardiographic
features (7,8) used as inclusion criteria for our
investigational group combined valve geometry and
ventricle function/geometry features, we hypothe-
sized that patients that exhibited those features
whether isolated or combined could have different
outcomes (i.e., whereas patients with the former
could be more likely to have impaired procedural
success and long-term efﬁcacy, patients with
ventricle function/geometry criteria would eventu-
ally reveal worse clinical outcomes). Although no
statistically signiﬁcant differences were observed in
our series, the combined group demonstrated
numerically lower efﬁcacy and higher rates of death
and MR $3þ through 12-month follow-up, but our
limited sample size and relatively short follow-up
period precluded deﬁnitive conclusions.
Due to the high anatomical complexity demon-
strated by the EVERESTOFF group, we used a number
of advanced techniques for clip placement, including
“aorta hugging” in cases of extremely deviated pos-
terior leaﬂet, use of rapid pacing in selected cases,
and performing the ﬁrst grasp close to the larger gap
to approximate leaﬂets and facilitate the second
grasp. A detailed description of these techniques will
be the subject of a future paper.
Finally, although a trend (p ¼ 0.073) toward the
implantation of more clips per patient was identiﬁed
in the EVERESTOFF group, the increased mitral valve
gradient observed in both groups at 12-month follow-
up was equivalent and not clinically concerning (i.e.,
most patients with mitral valve gradient <5 mm Hg).
These ﬁndings, coupled with the stability of MR
reduction over time reafﬁrm that, when needed,
the implantation of more than 1 MitraClip can be
accomplished in most cases without important con-
cerns regarding prohibitive increase in mitral valve
gradient, while keeping the effectiveness in terms
of MR reduction (22). The cost-effectiveness of
implanting more than 1 clip per patient, though,
remains to be determined (23).
The data herewith described are insightful as they
suggest a potential room for expanding the in-
dications of MitraClip implantation for the treatment
of 3þ to 4þ MR in high-risk surgical patients beyond
the initial criteria proposed by the EVEREST I and
II studies (7,8); nevertheless, additional research
with longer follow-up and larger sample sizes are
mandatory before any formal recommendation of
broadened indications for MitraClip therapy are
considered. Two important ongoing randomized
trials that estimate the inclusion of w1,200 patients
will certainly contribute to better elucidation of therole of MitraClip therapy in high surgical risk
patients with functional MR (COAPT [Clinical
Outcomes Assessment of the MitraClip Therapy
Percutaneous Therapy for High Surgical Risk
Patients]; NCT01626079) as well as the impact of this
novel therapy in patients with functional MR asso-
ciated with congestive heart failure (NYHA class III
or IV and 15% # EF #40%) (RESHAPE-HF [A
Randomized Study of the MitraClip Device in Heart
Failure Patients With Clinically Signiﬁcant Func-
tional Mitral Regurgitation]; NCT01772108). Taken
together, the results from these studies will shed
light on expanded indications of MitraClip implan-
tation, potentially opening a new avenue in the
research of percutaneous edge-to-edge treatment
of MR (24).
STUDY LIMITATIONS. Several things should be
considered in the interpretation of our results. First,
this was not a randomized controlled trial, therefore,
several confounding factors could have inﬂuenced
our results; nevertheless, the inclusion of consecutive
patients with balanced clinical characteristics might
have minimized potential selection bias. Second, a
relatively small sample size with limited follow-up
were included, thus our results should be repro-
duced in larger populations with longer follow-up
periods. Third, the echocardiographic parameters
analyzed at 12-month follow-up could have been
inﬂuenced by survival bias, but equivalent and
low rates of mortality exhibited in our study may
have attenuated this phenomenon. Fourth, 90% of
our patients were available for 12-month follow-up
due to insufﬁcient time elapsed since the index
procedure. Aiming at minimizing this potential
caveat, we made the analyses of the 12-month
primary efﬁcacy endpoint and its components sepa-
rately using Kaplan-Meier estimates. Fifth, the in-
terventions described were undertaken in a center
that performs a high volume of MitraClip implanta-
tions per year, therefore, our results should not be
generalized. Our echocardiographic data were not
reviewed by an independent core laboratory as it was
performed in a clinical setting, reﬂecting the real-
world practice; however, the analyses were conduct-
ed by dedicated, highly experienced physicians (12)
using validated methods and were based on
consensus.
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